Sei Investments Co. Boosts Stake in BioNTech SE (NASDAQ:BNTX)

Sei Investments Co. lifted its holdings in BioNTech SE (NASDAQ:BNTX) by 0.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 391,889 shares of the company’s stock after purchasing an additional 2,870 shares during the quarter. Sei Investments Co. owned 0.16% of BioNTech worth $48,818,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the business. NewEdge Advisors LLC raised its stake in shares of BioNTech by 1,009.6% in the first quarter. NewEdge Advisors LLC now owns 2,885 shares of the company’s stock worth $359,000 after purchasing an additional 2,625 shares during the last quarter. Sector Gamma AS grew its holdings in shares of BioNTech by 11.9% in the first quarter. Sector Gamma AS now owns 26,554 shares of the company’s stock worth $3,308,000 after acquiring an additional 2,816 shares during the period. Platinum Investment Management Ltd. grew its holdings in shares of BioNTech by 64.4% in the first quarter. Platinum Investment Management Ltd. now owns 63,338 shares of the company’s stock worth $7,890,000 after acquiring an additional 24,811 shares during the period. HighTower Advisors LLC grew its holdings in shares of BioNTech by 131.2% in the first quarter. HighTower Advisors LLC now owns 14,927 shares of the company’s stock worth $1,846,000 after acquiring an additional 8,472 shares during the period. Finally, FMR LLC grew its holdings in shares of BioNTech by 25.0% in the first quarter. FMR LLC now owns 228,144 shares of the company’s stock worth $28,420,000 after acquiring an additional 45,592 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Up 0.7 %

Shares of NASDAQ:BNTX opened at $121.75 on Friday. The business’s 50 day moving average is $109.93 and its 200 day moving average is $116.31. The company has a quick ratio of 10.32, a current ratio of 10.56 and a debt-to-equity ratio of 0.01. The stock has a market cap of $29.34 billion, a P/E ratio of 6.82 and a beta of 0.18. BioNTech SE has a 52-week low of $95.50 and a 52-week high of $188.99.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, August 7th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.04. BioNTech had a return on equity of 21.46% and a net margin of 47.37%. The company had revenue of $167.70 million during the quarter, compared to the consensus estimate of $628.13 million. During the same quarter in the prior year, the business earned $7.31 earnings per share. The company’s revenue was down 94.8% compared to the same quarter last year. Sell-side analysts predict that BioNTech SE will post 6.12 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on BNTX shares. HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price objective on shares of BioNTech in a report on Monday, August 28th. Morgan Stanley cut their price objective on BioNTech from $119.00 to $116.00 and set an “equal weight” rating for the company in a report on Tuesday, August 8th. Redburn Partners raised BioNTech from a “neutral” rating to a “buy” rating and boosted their price target for the company from $165.00 to $170.00 in a report on Wednesday, May 17th. Deutsche Bank Aktiengesellschaft cut their price target on BioNTech from $135.00 to $120.00 in a report on Thursday, May 18th. Finally, HSBC assumed coverage on BioNTech in a report on Friday, July 14th. They set a “buy” rating and a $124.00 price target for the company. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $158.69.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.